Measles and rubella elimination country profile: Georgia

Measles elimination status Rubella elimination status Total population 3 912 061 < 1 year old 49 439 < 5 years old 265 845 Demographic information, 2017 Source: World Population Prospects: The 2017 Revision, New York, United Nations Measles and rubella surveillance National case-based surveillance for measles, rubella and CRS Lab confirmation for diagnosis of measles, rubella and CRS Source: WHO/UNICEF Joint Reporting Form on Immunization, 2017 Measles and rubella elimination country profile Georgia Measles and rubella immunization schedule, 2017 Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/) and communication with the country MMR = measles-mumps-rubella vaccine; MCV1 = first dose measles-containing vaccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine Measles and rubella cases and immunization coverage, 2008–2017 Source: Disease incidence and immunization coverage (WUENIC), WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MCV1 = first dose of measles-containing vaccine MCV2= second dose of measles-containing vaccine Definition used for an outbreak Source: Measles and rubella elimination Annual Status Update report, 2017 At least two measles or rubella cases including cases with epidemiological links Confirmed measles cases by month of onset, 2013-2017 Source: CISID 2017 Vaccine Schedule MCV1 MMR 12 months MCV2 MMR 5 years Year of introduction MCV2 1986 RCV 2004 Measles vaccination in school No 2016 endemic 2017 endemic 2016 endemic 2017 interrupted 0 10 20 30 40 50 60 70 80 90 100 0 1000 2000 3000 4000 5000 6000 7000 8000 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 % co ve ra ge Nu m be r o f c as es Year Measles Rubella MCV1 coverage MCV2 coverage 0 500 1000 1500 2000 2500 3000 J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D 2013 2014 2015 2016 2017 N um be r of c as es Month and year Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvc Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvc Measles and rubella elimination country profile Georgia ©WHO 2019 Information on CRS, 2017 No cases reported Source: Measles and rubella elimination Annual Status Update report, 2017 CRS = congenital rubella syndrome Measles cases by first subnational level, 2017 Source: Measles and rubella elimination Annual Status Update report, 2017 Measles genotypes by first subnational level, 2017 Source: MeaNS 2017 Note: The dots in the maps are placed randomly within the administrative regions. Map disclaimer: The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Sources of infection, 2017 Measles Rubella Imported 2 0 Import-related 0 0 Unknown/ Not reported 0 0 Endemic 94 5 Source: Measles and rubella elimination Annual Status Update report, 2017 Measles cases by age group and vaccination status, 2017 Source: Measles and rubella elimination Annual Status Update report, 2017 Note: Excludes imported cases Supplementary immunization activities Year Target age Vaccine used % Coverage 2016 6-30Y MMR 23% 2015 2-30Y MMR 13% Source: Supplementary immunization activities, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MMR = measles-mumps-rubella vaccine ND = Data not available 1dot=1case •B3 •D8 •H1 •D4 0 20 40 60 80 100 < 1 1-4 5-9 10-14 15-19 20-29 30 + % o f c as es Age group (years) 0 doses 1 dose 2 or more doses Unknown Suspected measles cases Confirmed measles cases Discarded as non- measles Measles incidence Genotypes detected Laboratory Epi- linked Clinically Total 2013 8044 787 304 6783 7874 170 1756 D8 2014 3242 391 132 2668 3191 50 854.8 D8 2015 498 42 30 359 431 68 115.5 D8 2016 55 5 0 9 14 44 3.8 D8 2017 148 76 12 8 96 52 25.3 D8 Measles incidence, epidemiologic and virologic characteristics, 2013-2017 Measles surveillance and laboratory performance indicators, 2013-2017 Source: Measles and rubella elimination Annual Status Update report, 2013-2017 Incidence calculated per 1 million population ND = Data not available; NA= Not applicable Source: ASU 2013-2017 ND = Data not available; NA= Not applicable A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory Rubella incidence, epidemiologic and virologic characteristics, 2013-2017 Rubella surveillance and laboratory performance indicators, 2013-2017 Source: Measles and rubella elimination Annual Status Update report, 2013-2017 Incidence calculated per 1 million population ND = Data not available; NA= Not applicable Source: ASU 2013-2017 ND = Data not available; NA= Not applicable A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory Surveillance performance indicators and targets a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population b. % cases with adequate laboratory investigation: ≥ 80% c. % origin of infection known: ≥ 80% d. Rate of viral detection: ≥ 80% Measles and rubella elimination country profile Georgia Discarded non- measles rate % 1st sub- national unit with ≥ 2 discarded cases % cases with adequate laboratory investigation % origin of infection known # specimen tested for measles % positive for measles Rate of viral detection % WHO and proficient labs 2013 3.6 25% 100% 99.8% ND ND ND ND 2014 1.5 25% 14.4% 99.6% ND ND 100% ND 2015 1.8 33.3% 21.7% 99.8% 99 43.4% 55.5% ND 2016 1.2 8.3% 100% 100% 120 7.5% 100% 100% 2017 1.4 8.3% 85.8% 100% 127 59.8% 33.3% 94.5% Suspected rubella cases Confirmed rubella cases Discarded as non- rubella Rubella incidence Genotypes detected Laboratory Epi- linked Clinically Total 2013 260 6 1 217 224 31 50 ND 2014 177 2 0 147 149 26 39.9 ND 2015 138 0 0 100 100 37 26.8 ND 2016 106 1 0 11 12 91 3.2 ND 2017 66 1 0 4 5 61 1.3 ND Discarded non- rubella rate % 1st sub- national unit with ≥ 2 discarded cases % cases with adequate laboratory investigtion % origin of infection known # specimen tested for rubella % positive for rubella Rate of viral detection % WHO and proficient labs 2013 2.7 0% 100% 99.6% ND ND ND ND 2014 1.8 0% 40.9% 100% ND ND ND ND 2015 1 8.3% 20% 100% 25 0% 0 ND 2016 2.4 33.3% 97.5% 100% 129 1.6% 0 100% 2017 1.6 33.3% 86.4% 100% 57 1.8% 0 100% RVC comments, based on 2017 reporting The Regional Verification Commission for Measles and Rubella Elimination (RVC) commends the national verification committee for measles and rubella elimination (NVC), national health authorities and public health system on achieving interruption of endemic rubella transmission, and all efforts made towards measles and rubella elimination. The RVC urges further steps be taken to achieve and maintain high vaccination coverage with 2 doses of MRCV at all administrative levels and among all susceptibles. Surveillance sensitivity and measles genotyping need to be strengthened and rubella genotyp- ing initiated. ©WHO 2019 Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvc